851651-82-6Relevant articles and documents
Discovery of a Potent and Selective Covalent p300/CBP Inhibitor
Mastracchio, Anthony,Lai, Chunqiu,Digiammarino, Enrico,Ready, Damien B.,Lasko, Loren M.,Bromberg, Kenneth D.,McClellan, William J.,Montgomery, Debra,Manaves, Vlasios,Shaw, Bailin,Algire, Mikkel,Patterson, Melanie J.,Sun, Chaohong C.,Rosenberg, Saul,Lai, Albert,Michaelides, Michael R.
, p. 726 - 731 (2021)
Aberrant gene activation driven by the histone acetyltransferases p300 and CREB binding protein (CBP) has been linked to several diseases, including cancers. Because of this, many efforts have been aimed toward the targeting of the closely related paralog
URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C
-
Page/Page column 199, (2009/04/25)
Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.
THIAZOLIDINONES, PRODUCTION AND USE THEREOF AS MEDICAMENTS
-
Page/Page column 51, (2010/02/11)
-
